Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
Available as injection and nasal spray — a versatile GnRH agonist in hormone-dependent conditions.
Also known as: Suprefact · GnRH agonist
Part of the Foundational & therapeutic peptides cluster
Overview
Buserelin is a synthetic GnRH agonist peptide used to suppress sex-hormone production in hormone-dependent conditions. It is an approved prescription medicine for prostate cancer, premenopausal breast cancer, and endometriosis, and it is used in assisted reproduction protocols. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic GnRH analog
Primary research or clinical context: Approved medicine for prostate cancer, premenopausal breast cancer, endometriosis, and use in assisted reproduction (prescription)
Routes of administration
Buserelin is notable for being available both as a subcutaneous injection and an intranasal spray. The nasal route illustrates how peptide drugs can sometimes reach the circulation across mucosal surfaces, though bioavailability is lower than by injection.
Role in IVF
In assisted reproduction, GnRH agonists like buserelin are used to control the timing of ovulation by first suppressing endogenous gonadotropin surges. This lets clinicians coordinate ovarian stimulation more predictably.
Sequence
One-letter sequence commonly cited for Buserelin (educational; isoforms and modifications may differ):
XHWSYSLRP
X = non-canonical residue (N-terminal glutamic acid is pyrocarboxylic acid; serine residue at position 4 is 1,1-dimethylethyl-serine (t-Bu-Ser)). X marks a non-canonical residue — see the structure block below. (Plotted as alanine on the wheel.)
Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Buserelin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C60H86N16O13
- Average reference mass
- ≈ 1,239.4
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
N-terminal glutamic acid is pyrocarboxylic acid; serine residue at position 4 is 1,1-dimethylethyl-serine (t-Bu-Ser)
- PubChem CID: 50225
- IUPHAR ligand: 3860
- ChEMBL: CHEMBL2110824
- DrugBank: DB06719
- CAS RN: 57982-77-1
- UNII: PXW8U3YXDV
Chemistry values: IUPHAR/BPS Guide to Pharmacology, PubChem · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 42 registered studies with “Buserelin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT01492972 | Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | Phase 3 | recruiting | 2026-09-29 |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low | Phase 3 | active not recruiting | 2026-08-17 |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for | Phase 3 | active not recruiting | 2026-08-17 |
| NCT07553988 | A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | Phase 2 | active not recruiting | 2026-04-28 |
| NCT01546987 | Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-R | Phase 3 | completed | 2026-03-06 |
| NCT00936390 | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | Phase 3 | completed | 2026-03-06 |
Buserelin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Buserelin (source record; form not independently established)Average reference mass: 1,239.4 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Buserelin
What is Buserelin?+
Buserelin is a synthetic GnRH agonist peptide used to suppress sex-hormone production in hormone-dependent conditions. It is an approved prescription medicine for prostate cancer, premenopausal breast cancer, and endometriosis, and it is used in assisted reproduction protocols. This page is educational and is not medical advice.
What Canadian product status is recorded for Buserelin?+
Canadian product status for Buserelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Buserelin?+
Buserelin is commonly described as approximately 9 amino acids (GnRH agonist (nonapeptide analog)).
Related peptides
References & further reading
- 1.Bruun et al. (1986). [Buserelin (Suprefact)]. Ugeskr Laeger
- 2.Mohr (1994). [Buserelin]. Dtsch Med Wochenschr
- 3.Levy et al. (2007). A single subcutaneous administration of buserelin induces ovulation in the mare: field data. Reprod Domest Anim
- 4.Engmann et al. (2005). GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod
- 5.Chenault (1990). Effect of fertirelin acetate or buserelin on conception rate at first or second insemination in lactating dairy cows. J Dairy Sci
- 6.Brogden et al. (1990). Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile. Drugs
- 7.Manjarín et al. (2019). Effect of Oxytocin, Cloprostenol or Buserelin in Semen Doses on Sow Fertility. Animals (Basel)
- 8.Yu (2000). Dosage of buserelin. J Reprod Med
- 9.PubChem — compound summary for Buserelin (CID 50225)
- 10.Wikipedia — Buserelin